Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
26-week open-label extension study of asenapine in adolescents with bipolar I manic or mixed episodes
2010-022648-19Phase 3
- Sponsor
- Merck & Co.
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of asenapine in bipolar I disorder, sponsored by Merck & Co. Primary endpoint: Safety and tolerability of long-term asenapine treatment.
02
Drugs
asenapine
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2010-022648-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022648-19.